COMBIMATRIX

CombiMatrix Corporation develops proprietary technologies, products, and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology, and defense and homeland security. Its technologies include a platform to produce user-defined, in-situ synthesized, and oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations, and proteins. The company�s products and services include CustomArray platform, an oligonucleotide arra... y for genetic studies; DNA Array Synthesizer, an instrument that enables researchers to fabricate DNA arrays to their specifications; stripping reagents, which enable researchers to re-use microarrays; ElectraSense Reader, an electrochemical scanning instrument; and comparative genomic hybridization arrays, which are used for research and molecular diagnostic applications. It also offers proprietary molecular synthesis and screening methods for the discovery of potential new drugs. In addition, it operates as a diagnostics reference laboratory, which provides genetic diagnostics services through the use of arrays that utilize bacterial artificial chromosomes that enable genetic analysis to physicians, hospitals, and clinics. Further, the company develops a series of compounds to address various oncology-related diseases. Additionally, it involves in the development, manufacture, and sale of biosensor systems and technology for national defense and homeland security. The company sells its products and services directly, with partners, and through distributors to customers in the United States, Europe, and Asia. CombiMatrix Corporation was founded in 1995 and is based in Mukilteo, Washington.More